In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...
Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.
Oliver has an inherited condition called Hunter syndrome, which causes progressive damage to the body and brain.
A child with Hunter Syndrome has amazed doctors with his progress after becoming the first person in the world to receive a ...
Three years after the first ruling, the medical aid’s reconsideration bid thrusts the ongoing treatment dispute before the ...
11don MSN
California boy, 3, receives first-ever gene therapy for his rare disease: ‘It’s just so exciting’
A California toddler is the first person in the world to receive gene therapy to treat his devastating disease.
Oliver's gene therapy was confirmed to be working, with him thriving months after the treatment. Now, his speech, agility, ...
Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.
A medical breakthrough is giving new hope to families worldwide, as a three-year-old boy becomes first ever patient with ...
Three-year-old Ollie Chu, born with the rare and life-limiting Hunter syndrome, is showing improvement after receiving an ...
Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.
Pharmaceutical Technology on MSN
Denali makes $275m funding agreement with Royalty Pharma
Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback